<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773148</url>
  </required_header>
  <id_info>
    <org_study_id>RC-03773</org_study_id>
    <nct_id>NCT01773148</nct_id>
  </id_info>
  <brief_title>Access Safety and Efficacy Post Endovascular Intervention</brief_title>
  <acronym>ASPEN</acronym>
  <official_title>AXERA Access Safety and Efficacy Post Endovascular INtervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arstasis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arstasis, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess the safety and effectiveness of the AXERA Access System
      in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary
      Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or
      6F introducer sheath.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>Procedure through 30 day follow-up.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Absence of major access site-related complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 1-Day of Procedure.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as:
Successful placement of AXERA followed by procedural sheath
Achievement of hemostasis in conjunction with manual or mechanical compression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Hemostasis (TTH)</measure>
    <time_frame>Immediately following procedural sheath removal.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Elapsed time between sheath removal and first observed hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation (TTA)</measure>
    <time_frame>Evaluated at any time after 2 hours post sheath removal, until the subject successfully ambulated.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Elapsed time between sheath removal to time when subject stands and walks at least 20 feet without re-bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge, eligibility (TTD/e)</measure>
    <time_frame>Evaluated following sheath removal and ambulation and physical examination of the access site demonstrating stable access site.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Elapsed time between sheath removal and the time when subject is medically able to be discharged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge, actual (TTD/a)</measure>
    <time_frame>Evaluated following procedural sheath removal until actual discharge.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Elapsed time between sheath removal and the actual time when subject is discharged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>Procedure through 30 day follow-up.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Combined rate of minor vascular access-site related complications.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cardiovascular Disease.</condition>
  <arm_group>
    <arm_group_label>Arstasis Access System (AXERA) placement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arstasis Access System (AXERA)</intervention_name>
    <description>Placement of the AXERA device in the Femoral Artery.</description>
    <arm_group_label>Arstasis Access System (AXERA) placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18 years of age or older.

          -  Subject is clinically indicated for a PCI or PVI involving access through a 5F or 6F
             introducer sheath in the femoral artery.

          -  Subject is able to ambulate without assistance prior to the procedure and can be
             expected to ambulate (20 feet) within 2 hours post procedure.

          -  Female subjects of child bearing potential must have a negative pregnancy test.

        Exclusion Criteria:

          -  Subjects who are pregnant or lactating.

          -  Subject has a pre-existing severe non-cardiac systemic disease/illness or another
             reason that results in a projected life expectancy of less than 1 year.

          -  Subject has an active systemic or cutaneous infection or inflammation (e.g.,
             septicemia at the time of the procedure).

          -  Subject has systemic hypertension unresponsive to treatment (&gt;180mmHg systolic and
             &gt;110mm diastolic).

          -  Subject has significant bleeding coagulopathy or platelet disorder, (INR&gt; 2.0),
             including known thrombocytopenia (platelet count &lt;100,000/µL), thrombasthenia, Von
             Willebrand's disease, Factor V deficiency, or anemia (hemoglobin &lt;10 g/dL, or
             hematocrit &lt;30%).

          -  Subject presents with chronic renal insufficiency (creatinine ≥3.0mg/dl).

          -  Subject presents with hemodynamic instability or is in need of emergent surgery or
             emergent procedure.

          -  Subject presents with ST elevation myocardial infarction.

          -  Subject presents with unstable angina or non-ST elevation myocardial infarction and
             has troponin level &gt; 3 X upper limit of normal.  There must be at least one troponin
             level drawn &gt; 6 hours after onset of chest pain.

          -  Subject has received low molecular weight heparin &lt; 8 hours before vascular access,
             glycoprotein IIb/IIIa inhibitor &lt; 24 hours before vascular access, unfractionated
             heparin by infusion &lt; 1 hour before vascular access, or parenteral heparin at
             anticoagulant dose (as opposed to DVT prophylaxis)&lt; 6 hours before vascular access.

          -  Subjects who are clinically obese, defined as BMI &gt;40.

          -  Subject has received femoral artery Vessel Closure Implant (VCI) (suture or staple)
             at the target access site.

          -  Subject has received femoral artery VCI (collagen/PEG/PGA) at the target access site
             within 90 days of AXERA procedure.

          -  Subject is unable to routinely walk at least 20 feet without assistance (e.g.,
             requires a walker or wheelchair to mobilize, is leg amputee or has known paralysis)
             or unable to ambulate within 2 hours post procedure.

          -  Subject has had prior vascular surgery or vascular grafts at the target femoral
             artery access site.

          -  Subject has had a previous target femoral artery complication from angiography (such
             as pseudoaneurysm, Arteriovenous (AV) fistula, dissection), small CFA, abnormal,
             absent or weak distal ipsilateral pulse, or presenting with clinically significant
             peripheral vascular disease in the vicinity of the puncture.

          -  Subject has a high puncture (i.e. above the inferior reflection of the inferior
             epigastric artery).

          -  Subject has antegrade puncture.

          -  Subject has a stent in the ipsilateral common femoral artery.

          -  Subject is currently participating in an investigational drug or another device study
             that clinically interferes with the current study endpoints.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Dorogy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medical Center of Central Georgia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lilach Ofri</last_name>
    <phone>650-261-8043</phone>
    <email>lofri@Arstasis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Overman, BSN RN CCRC</last_name>
      <phone>256-519-8306</phone>
      <email>aoverman@theheartcenter.md</email>
    </contact>
    <investigator>
      <last_name>David Drenning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa New, RN, BSN</last_name>
      <phone>501-614-3619</phone>
      <email>Melissa.New@arheart.com</email>
    </contact>
    <investigator>
      <last_name>David Mego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Dumas</last_name>
      <phone>909-558-4000</phone>
      <phone_ext>46793</phone_ext>
      <email>PDumas@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Hilliard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Heart and Vascular Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Bordash, RN, BSN</last_name>
      <phone>916-453-4493</phone>
      <email>sarah.bordash@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Arvin Arthur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Medical Center</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Kozik, PhD,RN,CCRN</last_name>
      <phone>209-461-5257</phone>
      <email>Teri.Kozik@DignityHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Therese Connolly</last_name>
      <phone>209-461-5275</phone>
      <email>therese.connolly@dignityhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Gurinder Grewal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Knott, RN, BSN, MPH</last_name>
      <phone>478-633-7628</phone>
      <email>knott.carrie@mccg.org</email>
    </contact>
    <investigator>
      <last_name>Mark Dorogy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Opelousas General Health System</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey Huffman, LPN/CRC</last_name>
      <phone>337-407-3203</phone>
      <email>lacey.huffman@cardio.com</email>
    </contact>
    <investigator>
      <last_name>Kalyan Veerina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Bliden, BS, MBA</last_name>
      <phone>410-601-4795</phone>
      <email>kbliden@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Paul A Gurbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Findley, RN, BSN</last_name>
      <phone>601-268-5794</phone>
      <email>frances.findley@hattiesburgclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Janet Byrd, RN</last_name>
      <phone>601-268-5800</phone>
      <email>janet.byrd@hattiesburgclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Wilkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Long, RN</last_name>
      <phone>662-377-7571</phone>
      <email>along@nmhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Marsha Jones, RN,BSN,CCRP</last_name>
      <phone>662-377-7456</phone>
    </contact_backup>
    <investigator>
      <last_name>Barry Bertolet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Rose Dominican</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Abano, RN</last_name>
      <phone>702-933-9419</phone>
      <email>cabano@hcpnv.com</email>
    </contact>
    <investigator>
      <last_name>Herbert Cordero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candida Barlow, MSN RN</last_name>
      <phone>918-744-2685</phone>
      <email>Candida.barlow@sjmc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Haas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lexington Medical Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Sherriff, RN,MHA,CCRC</last_name>
      <phone>803-744-4909</phone>
      <email>ldsherriff@lexhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah A. Watkins, RN, MHA</last_name>
      <phone>253-426-6736</phone>
      <email>deborahwatkins@fhshealth.org</email>
    </contact>
    <investigator>
      <last_name>Theodore Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
